Introduction
Xenobiotics, such as drugs and environmental chemicals, exert a profound influence on human health. Xenobiotics can alter homeostasis and induce deleterious metabolic perturbations. In order to promote the metabolic inactivation and excretion of these compounds, multiple signalling pathways are activated to trigger hepatic biotransformation, biliary excretion and renal elimination. Part of these clearance mechanisms are coordinately controlled by nuclear receptors such as Pregnane X Receptor (PXR/NR1I2) and Constitutive Androstane Receptor (CAR/NR1I3). Being important transcription factors controlling xenobiotic detoxification, CAR and PXR display a strong expression in the primarily exposed organs, the liver and the intestine ( ; ). 1999
Through their DBD, CAR and PXR bind to various response elements (direct repeats DR3, DR4 and DR5 as well as everted repeats ER6 and ER8), thereby controlling the expression of a large set of target genes involved in energy metabolism and hormone homeostasis, inflammation, cell differentiation, bile acids and bilirubin detoxification ( ; ; Moreau 2008 et al. Pascussi and Vilarem 2008 Wada et al. 2 12 ). Moreover, this versatile DNA binding property allows cross talks between CAR and PXR, and also with other nuclear receptors 2009 such as FXR, LXR, VDR, PPAR, ER, GR, COUP-TFI and II ( ; ; ; Breuker 2010 et al. di Masi A. 2009 et al. Faucette 2006  ). 2011 et al. Istrate 2010 et al. PXR and CAR have been initially described as xenobiotic sensors modulating the expression of several hepatic target genes driven by a so-called xenobiotics response element and involved in detoxification pathways, including drug-metabolizing enzymes and transporters diminished therapeutic efficacy of many drugs and also potentially produces toxic metabolites. There is therefore a need to determine the effects of each novel therapeutic compound on PXR activity.
Recently, a novel antibacterial compound called walrycin A (4-methoxy-1-naphthol) has been identified through a high throughput screening approach and shown to target the WalK/WalR two-component signal transduction system of Gram ( ) bacteria such as
). Given that walrycin A belongs to a potential novel class of antibacterial Staphylococcus aureus and Bacillus subtilis Gotoh 2010 et al. compounds, effects on human xenobiotics metabolism and hepaotoxicity remain to be studied. Here we report that walrycin A modulates human PXR activity and impacts on hepatic cell viability.
Materials and Methods

Materials
Rifampicin, 6-methoxy-1-naphtol (6MNol) and 4-methoxy-1-naphtol (walrycin A), purchased from Sigma-Aldrich (St-Louis, MO, USA) were dissolved in dimethylsulfoxyde (DMSO). The housekeeping gene ribosomal protein large P0 ( , NM_001002.3) RPLP0 forward (CATGCTCAACATCTCCCCCTTCTCC) and reverse (ATGCAGCCCCGAATGCT CCTCATCGTGGCC) primers, CYP3A4 (NM_017460.5) forward (CATTCCTCATCCCAA TTCTTGAGGT) and reverse (CCACTCGGTGCTTTTGTGTATCT) primers and PXR isoforms 1 (NM_003889.3) and 2 (NM_022002.2) forward (ACCTTTGACACTACCTTCT CCCAT) and reverse (CGCAGCCACTGCTAAGCA) primers were purchased from Sigma-Aldrich (St Quentin-Fallavier, France)
Cell culture and treatment
The immortalized human hepatocyte (IHH) cell line was established by F. Kuipers (University Medical Center, Groningen, Netherlands) from primary human hepatocytes. Cells were routinely maintained as previously described ( ). Schippers 1997 et al.
Twenty-four hours before treatment, cells were seeded (3.10 cells per well) in 12-well plates in seeding medium (phenol-red free 5 Dulbecco s Modified Eagle Medium (DMEM) supplemented with 2 g/L glucose, 2 mM glutamine (Invitrogen Life Technologies, ' Carlsbad, CA, USA), 7 g/mL bovine insulin (Sigma-Aldrich), 100 U/mL penicillin (Invitrogen), 100 g/mL streptomycin (Invitrogen) μ μ and 10 charcoal dextran-stripped fetal calf serum (CD-FCS). Cells were washed once before treatment with stimulating medium % (seeding medium with CD-FCS reduced to 1 ) and treated for 24 h by compounds at indicated concentrations ( IHH cells were seeded 24 hours before transfection in 6-well plates (10 cells per well) in maintenance medium ( 6 Schippers 1997 et al.
). Cells were transfected using 0.1 nmol of ON-TARGETplus SMARTpool hPXR siRNA or non-targeting siRNA using the Dharmafect1 transfection reagent according to the manufacturer s protocol (Thermo Fisher Scientific, Lafayette, CO, USA). After a 24 h incubation, ' cells were washed with seeding medium and incubated further for 24 h. Cells were then washed with stimulating medium and treated as described above.
RNA extraction, reverse transcription and real time qPCR
At indicated times, cells were washed with 1x phosphate buffer saline (1x PBS) and total RNA was extracted using the Extract-all reagent (Eurobio, Courtabeuf, France) according to the manufacturer s protocol. One g of total RNA was reverse-transcribed using the ' μ High Capacity Reverse Transcription Kit (Applied Biosystem, Life Technologies, Carlsbad, CA, USA) according to the manufacturer s ' protocol. A 1:20 dilution of cDNA was then amplified by real time qPCR using Brilliant II Fast SybR Green Master Mix (Agilent Technologies, Santa Clara, CA, USA) and specific primers in a Stratagen Mx3005P QPCR System (Agilent Technologies). Gene expression levels were normalized using the housekeeping gene expression level as internal control. Fold induction were expressed RPLP0 as the ratio of the gene induced expression level to that of the basal level arbitrarily set to one.
Western blotting
At indicated times, transfected cells were washed with 1x PBS followed by total protein extraction using 100 L of Cell Lysis Buffer μ (Cell Signaling Technology, Beverly, MA, USA) according to the manufacturer s protocol. Western blotting was performed using 40 g of ' μ total proteins. hPXR protein expression was monitored using an anti-hPXR mouse monoclonal antibody (Perseus Proteomics Inc, Tokyo, Japan) and a HRP-conjugated goat anti-mouse secondary antibody (Sigma-Aldrich). The immune complexes were detected by chemiluminescence using Pierce ECL-plus Western Blotting Substrate (Thermo Fisher Scientific) according to the manufacturer s protocol ' and visualized with a G:Box gel dock system (Syngene, Cambridge, UK). HSP90 protein was used as internal standard for equal loading using a rabbit anti HSP90 antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) and a HRP-coupled goat anti rabbit as secondary antibody (Sigma-Aldrich). radiolabeled receptor (5 L of TnT mix) was carried out using increasing concentrations of chymotrypsin ranging from 1 to 5 g/mL. After μ μ a 10 min. incubation, digestion was stopped by the addition of 6X Laemmli buffer. Samples were boiled for 5 min. and separated by 12% SDS-PAGE. After gel drying, radiolabeled digestion products were visualized using a STORM Phosphorimager (GE Healthcare, Orsay, France).
Limited proteolysis assay
Gene reporter assay
The stable reporter cell line HGPXR stably expressing a GAL4DBD-hPXR LBD chimeric fusion protein was described previously ( 
Methods for computer-simulated ligand binding (docking)
Protein input files preparation
Ligand-free PXR (1ILH.pdb and 3HVL.pdb) input files were generated using the protein preparation wizard from the Maestro software (Maestro 8.5, Academic Campaign, ). The bond orders were assigned and hydrogen atoms were http://www.schrodinger.com added. The resulting receptor coordinates were saved as a pdb file.
Ligand input files preparation
Ligand input structures were generated and 3D-optimized with the MarvinSketch Academic Package (MarvinSketch 5.4.1.1, 2011, ChemAxon ) . Ligand structures were saved as mol2 files. http://www.chemaxon.com
GOLD and FRED docking protocol
Docking was performed using chemscore fitness function under standard default settings in the GOLD software (Cambridge Crystallographic Data Centre 12 Union Road, Cambridge, CB2 1EZ, UK, ): search efficiency: 200 , http://www.ccdc.cam.ac.uk % population size 100, number of islands 5, number of operations 100,000, niche size 2, migrate 10, mutate 95, cross over 95 and a selection pressure of 1.1. Early termination was allowed if 4 solutions were within 1.5 angstroms of root mean square deviation (RMSD). Docking with FRED 2.2.5, (OpenEye Scientific Software, Inc., Santa Fe, NM, USA, , 2011) was performed using Chemgauss3 www.eyesopen.com scoring for exhaustive search and Chemgauss3 scoring for optimization.
Viability assays
HepG2 cells were seeded in 96-well plates (10 cells per well) in maintenance medium and incubated for 24 hours. Cells were treated 4 for 24 h with indicated concentrations of compounds. Cell viability was quantified using the CellTiter 96 Non-Radioactive Cell Proliferation Assay (Promega) according to the manufacturer s protocol. Absorbance was monitored on MRX spectrophotometer (Thermo ' Labsystems, Issy Les Moulineaux, France). Results were calculated as follows: was determined using a one-way ANOVA followed by a Dunnett s multiple comparison post-hoc test (p-values<0.01 were considered as ' significant). For knock-down assays, significant differences were determined using a two-way ANOVA followed by a Bonferroni post-hoc test.
Results
Walrycin A regulates mRNA expression of genes involved in phase I drug metabolism
Walrycin A harbors potent antibacterial activity against the methycillin-resistant (MRSA) strain N315 ( ).
S. aureus
Gotoh 2010 et al. could result form PXR activation. In addition, this indicated that IHH cells provide a valid experimental model to evaluate specific PXR response upon exposure to xenobiotics.
Dose-dependent activation of by walrycin A is PXR-dependent CYP3A4
We further assessed the contribution of PXR to the observed alteration of the gene expression pattern. IHH cells were treated in parallel for 24 hours with the PXR reference agonist rifampicin or walrycin A or the walrycin A structural analogue 6MNol. As expected, rifampicin induced mRNA expression in a dose-dependent manner ( ) with an EC~1 M reaching a plateau starting at CYP3A4 Figure 2A Figure 2B results indicate that walrycin A activates signalling pathway(s) controlling mRNA expression. CYP3A4
We then hypothesized that walrycin A-induced mRNA expression was PXR-dependent. To assess this possibility, CYP3A4 PXR knock-down was performed in IHH cells using siRNAs ( ). Both mRNA and protein were significantly Figure 2C and 2D PXR downregulated upon anti-PXR siRNA treatment ( ), whereas a non-specific siRNA did not affect expression. Figure 2C PXR CYP3A4 mRNA was induced upon rifampicin treatment, whereas knock-down significantly blunted this response ( ). Importantly, PXR Figure 2D walrycin A-induced mRNA expression was decreased upon knock-down, but not affected by the non-specific siRNA ( CYP3A4 PXR
). Thus, induction of expression in response to walrycin A is a PXR-dependent process. Figure 2D CYP3A4
Walrycin A interacts with PXR and modifies its conformation
As we demonstrated that the induction of by walrycin A is PXR-dependent, we next hypothesized that walrycin A could CYP3A4 directly interact with PXR. To assess this possibility, limited proteolysis experiments were performed to probe potential structural modifications of the PXR polypeptide upon walrycin A binding. Full-length PXR was translated using S-labelled methionine in in vitro 35 the presence of either DMSO (negative control), rifampicin (positive control), walrycin A or the related compound 6MNol. Unliganded 5 12 and liganded PXR were then submitted to limited proteolysis using increasing concentrations of chymotrypsin ranging from 0.5 g/mL to μ 5 g/mL ( ). Full-length radiolabeled PXR protein was more amenable to degradation by chymotrypsin in the presence of μ Figure 3 rifampicin compared to negative control (1 DMSO), leading to several proteolysis resistant peptides ( ). The PXR proteolysis % Figure 3 pattern in the presence of walrycin A was totally different to that induced by DMSO, suggesting that walrycin A, like rifampicin, interacts with PXR and modifies its conformation, hence exposing chymotrypsin cleavage sequences. The digestion pattern generated in presence of 6MNol was comparable to that observed in the presence of DMSO, indicating that this compound is unlikely to bind PXR. These results are in line with the (lack of) effect of these compounds on PXR-mediated induction of expression. CYP3A4
Walrycin A activates PXR through its ligand binding domain
Since protease-resistant fragments observed in limited proteolysis assays can be attributed to structural alterations occurring in the activates PXR through its LBD and is likely to be a novel ligand for this nuclear receptor.
The walrycin A oxidation product Russig s blue is efficiently docked into the PXR LBD '
Having shown that walrycin A can alter PXR conformation and activates PXR through its LBD in cellular assays, we next in vitro analyzed the ability of walrycin A, of the closely related molecule 6MNol, and of Russig s blue, an oxidation product of walrycin A ( ). Ranking ligand fit in 3HVL showed that Russig s blue has the highest score ' Figure 5B ' compared to walrycin A and 6MNol, using either GOLD or FRED softwares ( ). Similar conclusions were drawn when using Figure 5B other PXR LBD coordinates (1ILH), corresponding to the human PXR LBD co-crystallized with SR12813 but without a coactivator peptide (data not shown). These data suggest that walrycin A may dock into the PXR LBD in its oxidized form Russig s blue.
'
Walrycin A and hepatic cells viability
Rifampicin and walrycin A share common bactericidal properties, raising the possibility of a combined antibacterial therapy. We therefore investigated the effect of walrycin A alone or in combination with rifampicin on the viability of human hepatoma cell lines IHH a n d H e p G 2 . C e l l v i a b i l i t y a s s a y s w e r e p e r f o r m e d u s i n g M T S (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) as a substrate for mitochondrial reductase.
To assess walrycin A toxicity, cells were independently exposed for 24 h to walrycin A and 6MNol concentrations increasing from 2 M μ up to 5 mM, whereas rifampicin concentrations were from 0.5 M to 1 mM. Walrycin A concentrations up to 156 M did not affect HepG2 μ μ viability ( ). Walrycin A IC was calculated to be 240 M, indicating that this compound impacted cell viability at a Figure 6A 50 μ concentration lower than that of rifampicin IC~1 mM, and ( ) and 6MNol (IC~1.7 mM, data not The potential synergy between walrycin A and rifampicin was then assessed in the MTS assay. HepG2 cells were exposed to increasing concentrations of rifampicin (from 3 M to 100 M) with or without 50 M walrycin A for 24 or 48 hours ( were obtained by exposing HepG2 cells to increasing concentrations of walrycin A (from 3 M to 100 M) together with rifampicin 10 M μ μ μ ( ). Taken together, these results indicated that rifampicin and walrycin A synergistically impacted human Supplementary figure S4 hepatoma cell viability in a dose-and time-dependent manner.
Discussion
Bacterial infections, despite intense efforts to thwart them, remain a major public health problem not only in developing but also in occidental countries, as highlighted by the reminiscence of nosocomial infections. mortality rates caused by these drug-resistant bacteria and the difficulty to develop novel potent and specific antibiotics targeting these bacterial pathogens, combined antibactericidal treatments are currently used to kill increasingly common antibiotic resistant-strains.
Rifampicin harbors valuable properties in combination with first-line antibiotics, and the combination of rifampicin and vancomycin is an effective treatment against nosocomial MRSA-induced pneumoniae ( combination with other antibiotics such as rifampicin, since its high minimal inhibitory concentration on MRSA (734 M) precludes its use μ as a standalone therapy.
However, drug-drug interactions induced upon antibiotics (co)treatment may lead to increased cytotoxicity as exemplified by liver damage, and to reduced efficiency due to rapid drug inactivation resulting from the activation of the nuclear xenobiotic sensors CAR and PXR (
). Evaluating the activity of walrycin A on hepatic functions is therefore critical to evaluate its potential usefulness Singh 2011 et al.
as an anti-MRSA drug.
The structure of walrycin A is based on a naphthalen scaffold, conferring hydrophobic properties, substituted by alcool and methoxy functions in position 1 and 4 respectively. As described by Gotoh , walrycin A targets the WalK/WalR two-component signal et al. expression was enhanced in a PXR-dependent manner upon walrycin A treatment. Owing to its structure, walrycin A can potentially activate PXR through direct binding or by triggering post-translational modifications of this nuclear receptor. To sort out these non-exclusive hypotheses, we investigated whether walrycin A is a direct activator of PXR. Using limited proteolysis and gene in vitro reporter assays, we demonstrated that walrycin A is likely to act through the PXR LBD. However, in silico docking of walrycin A into the PXR ligand binding pocket revealed that the walrycin A oxidation product, Russig s blue, is more likely to behave as a bona-fide PXR ' ligand. This is consistent with the fact that walrycin A spontaneously oxidizes in various aqueous solutions ( and our Shoji et al. 2010 unpublished observations), and with the strict stereoselectivity of PXR activation, on which the structurally related 6MNol is inactive and unable to convert into a spectrally detectable compound (our unpublished observations).
Activation of PXR is known to be species-specific, and several reports document the irrelevance of rodent models for assessing the ability of xenobiotics to regulate human PXR activity ( ; ;
). Importantly, the expression of Jones 2000 et al.
Lecluyse 2001 prediction of biological outcomes following CAR ctivation in the liver, and certainly deserves further investigation.
In addition to its PXR and CAR modulatory effects, walrycin A exhibited weak cytotoxic properties on human hepatoma cells, but synergistically increased rifampicin toxicity and vice-versa. This suggests that a combination of rifampicin and walrycin A could induce deleterious hepatic effects . This drawback has also been reported for the vancomycin/ rifampicin combined treatment ( in vivo Jung et al. ) , which is likely due at least in part to drug-drug interactions. Finally, we noted that some walrycin A-exposed mice exhibited a 2010 marked splenomegaly, in agreement with a study in rats ( ), and which might stem also from a portal Eastman Kodak Co. Finally, to the best of our knowledge, walrycin A is not yet validated as a therapeutically usable drug and there is therefore no information on human exposure level. Nevertheless, as this compound and/or its derivative Russig s blue activate PXR and CAR, hepatic ' effects of a simultaneous exposure to walrycin A and to other drugs should be considered in the future. As walrycin A is also a widely used compound in chemical synthesis ( ), the effects of a fortuitous acute or chronic exposition should be Talaat and Nelson 1986 monitored in workers exposed to this compound, especially since combined, unwanted exposure to other environmental pollutants such as phthalates and bisphenol A, also known to activate human PXR and CAR ( ), can dangerously impact health ( DeKeyser 2011 et al. : Phase I enzymes differentially C expressed in response to walrycin A treatment (fold-change>4). The gene list was clustered in 3 main families (alcool deshydrogenase, aldehyde dehydrogenase and cytochrome p450). Enzymes not belonging to these 3 main families are labeled as others .
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Figure 2
Dose-dependence activation of by walrycin A is PXR-dependent CYP3A4 IHH cells were treated for 24h with indicated concentrations of rifampicin (black bar 
C:
Cells were transfected with control siRNA (white bars) or by PXR-targeting siRNA (black bars) and knock-down expression of gene PXR (mRNA and protein) was assessed by qPCR and western blot analysis.
Control and PXR-targeting siRNA transfected cells were treated D:
24h by vehicle (0.1 DMSO), rifampicin or walrycin A. The expression of and was determined by qPCR, normalized to % PXR CYP3A4 expression level and expressed relative to that detected in cells transfected by control siRNA. Histograms represent means SEM of a RPLP0 ± representative experiment performed in triplicate. Statistical significances were determined using a Bonferroni post-hoc test ( p<0.001 and *** * p<0.01).
*
Figure 3
Walrycin A induces conformational changes in the human PXR receptor polypeptide translation of hPXR was carried out in the presence of 0.1 DMSO, 50 M 6MNol, walrycin A or rifampicin. Upon completion of In vitro % μ protein synthesis, limited proteolysis assay was performed as described in materials and methods using varying concentrations of chymotrypsin (up to 5 g/mL). Radio-labeled peptides were detected using a Phosphorimager system. Arrow indicates the short fragments μ corresponding to LBD of PXR partially protected from digestion in presence of rifampicin or walrycin A.
Figure 4
Walrycin A activates PXR through its ligand binding domain HeLa cell line in which a chimeric GAL4-DBD-PXR LBD fusion protein was stably expressed was treated with DMSO (negative control), SR12813 (positive control), walrycin A or 6MNol. Cells were treated with increasing concentrations of walrycin A ranging from 0.5 M to A: μ %
Figure 5
The walrycin A oxidation product Russig s blue fits in PXR ligand-binding pocket ' Images of docking solutions for SR12813, Russig s blue, Walrycin A and 6MNol in PXR ligand-binding domain from 3HVL. Endogenous A: ' 3HVL SR12813 ligand is shown in magenta and three solutions for each ligand are shown in gold. Oxygen atoms are shown in red except in the reference ligand (magenta).
Ligand fitting in 3HVL and 1ILH ligand-binding pockets as assessed with GOLD (Chemscore, good fitting B:
results in high score) and FRED (FRED score, good fitting results in low score). Russig s blue and SR12813 grouped as best fitting ' compounds compared to walrycin A and 6MNol.
Figure 6
Impacts of rifampicin and Walrycin A on hepatoma cell viability HepG2 cells were treated for 24h using compounds concentrations ranging from 2 M to 5 mM for walrycin A and from 0.5 M to 1mM A: 
